STAT+: AbbVie skin disorder drug succeeds in late-stage trial, but results miss market expectations

How 1 sources are covering this

• STATCenter·1h ago

  STAT+: AbbVie skin disorder drug succeeds in late-stage trial, but results miss market expectations

  AbbVie's lutikizumab, an experimental therapy for a chronic skin condition, succeeded in a late-stage trial but missed market expectations.

  Read at STAT →